Patient description: Patient A is a 30-year-old male who was admitted to the hospital after 10 days of cough, profuse nocturnal sweating and loss of appetite. He had traveled to India 1 months ago and has not any positive history of TB vaccination. He is a previously healthy man, working as an engineer in a high tech company. He doesn't smoke o use any illicit drugs. He was febrile (38 c) with heart rate of 115 b/min, respiratory rate of 22, BP of 125/75 mmHg and O2 sat of 97%. Chest X-ray showed infiltrate in the middle of left lung with diameter of 1.8 cm with signs of cavitation. The sputum smear revealed positive sputum culture for Mycobacterium tuberculosis which are sensitive of the first-line TB drugs (isoniazid, streptomycin, rifampicin and ethambutol). Lab study is reported bellow: Hgb: 13 g/dl WBC: 14000 /mm3 Plt: 300000 /ml AST: 13 U/L ALT: 15 U/L Alk P: 53 U/L Bill total: 0.6 mg/dl Na: 137 mEq/l K: 4 mEq/l Creatinine: 0.5 mg/dl BUN: 10 mg/dl ESR: 120 mm/hr

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Covid19 Anosmia Fever Cough Shortness of Breath Sore Throat Nausea Vomiting Headache Muscle Weakness Pain, Muscle Pain, Chest Pain, Joint Pain, Abdominal Pain Irritable Mood Confusion Covid-19 positive by polymerase chain reaction (PCR) testing Participant must be able to evaluate their symptoms and report them in the symptoms diary Patients must be able to take their oral temperature daily with an electronic thermometer provided to them with study materials Males and females, at least 18 years of age, capable and willing to provide informed consent Female patient is either not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile, or is of childbearing potential and practicing at least one method of contraception and preferably two complementary forms of contraception including a barrier method (e.g. male or female condoms, spermicides, sponges, foams, jellies, diaphragm, intrauterine device (IUD)) throughout the study Patient must have received a diagnosis of COVID-19 infection within the last 48 hours and have one or more symptoms Outpatient setting (not currently hospitalized or under immediate consideration for hospitalization) Patient must be able and willing to comply with the requirements of this study protocol  Patient currently hospitalized or under immediate consideration for hospitalization Patient currently in shock or with hemodynamic instability Patient undergoing chemotherapy for cancer Patient is unable to take oral temperature using an electronic thermometer Patient who received at least one dose of the COVID-19 vaccine Female patient who is pregnant or breast-feeding or is considering becoming pregnant during the study People taking anticoagulant/antiplatelet medications, those with bleeding disorders, and people two weeks before or after surgery Patient is considered by the investigator, for any reason, to be an unsuitable candidate for the study Regular consumption of natural products containing more than 150 mg of hesperidin or regular consumption of more than 1 glass of orange juice per day Known allergy to any of the medicinal and non-medicinal ingredient: hesperidin, microcrystalline cellulose, magnesium stearate